
Explore the key conclusions around aiming for higher treatment targets, discussed at the UCB-sponsored Satellite Symposium presented at EULAR 2023.
Professor Diamant Thaçi is Director and Professor at the Institute and Comprehensive Centre for Inflammation Medicine, University of Lübeck, Germany. Professor Thaçi is also Chairman of the Inflammatory Board at the University Hospital Schleswig-Holstein, Lübeck Campus.
He is an active member of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), the International Psoriasis Council (IPC), the International Eczema Council (IEC), and the Skin Inflammation & Psoriasis International Network (SPIN). His research interests cover immunological work in basic research and all stages of clinical drug development, with a focus on chronic inflammatory skin diseases.
Treatment for PsA should target a broad range of musculoskeletal and extra-articular manifestations.1 Listen to Assoc. Prof Philipp Sewerin explain how MDA can...
Explore the key conclusions around aiming for higher treatment targets, discussed at the UCB-sponsored Satellite Symposium presented at EULAR 2023.
axSpA is a complex disease with a significant burden on many aspects of daily life.1,2 Dive into the importance of ASAS40 for your patients with Dr Fabian Proft.
Watch Prof Robert Landewé discuss the importance of using ASDAS <2.1 as a treatment target for patients with axSpA.
Read our key takeaways from the 2022 ASAS-EULAR recommendations for the management of axSpA, presented as part of Dr Sofia Ramiro's workshop at UCB Summit 2023.
Watch Prof Lars Erik Kristensen and Prof Frank Behrens discuss the role of the IL-17 family of cytokines in SpA pathobiology.